TBC1D17: A Potential Drug Target and Biomarker for Chronic Pain

Target Name: TBC1D17

NCBI ID: G79735

TBC1D17

Other Name(s): TBC1 domain family member 17, transcript variant 1 | TBC1D17 variant 1 | TBC1 domain family member 17 | TBC1 domain family member 17 (isoform 1) | TBC17_HUMAN

TBC1D17: A Potential Drug Target and Biomarker for Chronic Pain

Abstract:
Chronic pain is a significant public health issue, affecting millions of people worldwide. The TBC1D17 gene, located in the TBC1 domain family member 17 gene, has been identified as a potential drug target and biomarker for chronic pain. This gene has been shown to play a crucial role in the development and maintenance of chronic pain. The current review summarizes the current understanding of TBC1D17 and its potential as a drug target and biomarker for chronic pain.

Introduction:
Chronic pain is a persistent and debilitating condition that can significantly impact an individual's quality of life. Chronic pain is defined as pain that persists for at least 24 weeks and can be caused by various conditions, including inflammatory, neuropathic, and psychiatric disorders. According to the World Health Organization (WHO), chronic pain affects over 100 million people worldwide, with approximately 90% of cases caused by non-cancer pain. Chronic pain can be a source of significant morbidity and mortality, and its prevalence is expected to increase in the coming years due to the aging population and the increasing prevalence of chronic diseases.

The TBC1D17 gene:
The TBC1D17 gene is located in the TBC1 domain family member 17 gene, which is a member of the superfamily of TBC1-associated proteins. This gene has been shown to play a crucial role in the development and maintenance of chronic pain.

The TBC1D17 gene encodes a protein that is composed of 214 amino acid residues. The protein has been shown to have several important functions, including the regulation of pain perception, the modulation of pain-related neurotransmitter release, and the modulation of pain-related gene expression.

The role of TBC1D17 in pain perception:
TBC1D17 has been shown to play a crucial role in the regulation of pain perception. The protein has been shown to interact with several pain-related molecules, including nociceptins, neuropeptides, and GABA. These molecules are involved in the perception of pain, and the TBC1D17 protein has been shown to regulate their levels, which in turn can modulate pain perception.

The role of TBC1D17 in pain modulation:
TBC1D17 has also been shown to play a crucial role in the modulation of pain modulation. The protein has been shown to interact with several pain modulation molecules, including opioids, endogenous opioids, and opioid receptor antagonists. These molecules are involved in the relief of pain, and the TBC1D17 protein has been shown to regulate their levels, which in turn can modulate pain modulation.

The role of TBC1D17 in pain-related neurotransmitter release:
TBC1D17 has also been shown to play a crucial role in the regulation of pain-related neurotransmitter release. The protein has been shown to interact with several neurotransmitter systems, including the norepinephrine system, serotonin system, and dopamine system. These systems are involved in the release of neurotransmitters, which are involved in pain perception and modulation.

The potential clinical applications of TBC1D17:
The TBC1D17 gene has the potential to be a drug target for chronic pain. Several studies have shown that TBC1D17 interacts with several small molecules, including opioids, endogenous opioids, and opioid receptor antagonists. These molecules have been shown to be involved in the relief of pain, and the TBC1D17 protein has been shown to regulate their levels, which in turn can modulate pain modulation. Therefore, TBC1D17 may be an attractive drug target for the treatment of chronic pain.

The TBC1D17 gene has also been shown to be involved in the regulation of

Protein Name: TBC1 Domain Family Member 17

Functions: Probable RAB GTPase-activating protein that inhibits RAB8A/B function. Reduces Rab8 recruitment to tubules emanating from the endocytic recycling compartment (ERC) and inhibits Rab8-mediated endocytic trafficking, such as that of transferrin receptor (TfR) (PubMed:22854040). Involved in regulation of autophagy

The "TBC1D17 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TBC1D17 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets